Huadong Medicine and SynerK Announce Strategic Collaboration to Co-Develop Novel siRNA Drug SNK-2726 for Hypertension
Huadong Medicine
Large Comprehensive Pharmaceutical Product Developer
Synerk
Small Nucleic Acid Drug Developer
SNK-2726, currently in the IND application preparation stage, is a siRNA drug with independent intellectual property rights developed by Synerk. According to the cooperation agreement, both parties will jointly advance the development of SNK-2726 to a certain stage. Meanwhile, Huadong Medicine will obtain an exclusive option and can pay an exercise fee in the future to acquire the exclusive rights for the development, registration, manufacturing, and commercialization of SNK-2726 in Greater China. After Huadong Medicine exercises the option, Synerk will be entitled to receive subsequent R&D milestone payments and sales milestone payments, as well as tiered royalties based on net sales after commercialization.
Synerk CEO Dr. Lan Tao stated:"We are very honored to cooperate with Huadong Medicine. The corporate philosophy of Huadong Medicine, 'research-based and patient-centered', aligns perfectly with our mission to 'transform patients' lives'. This collaboration further validates the potential of Synerk's GalNexus siRNA drug platform. Through this synergistic cooperation where 1+1>2, we are hopeful to jointly accelerate the development of novel drugs and bring new treatment options to patients."
Lü Liang, Chairman and General Manager of Huadong Medicine, said:"We are delighted to reach this strategic cooperation with Synerk to jointly develop the siRNA innovative drug SNK-2726. Synerk owns a novel nucleic acid drug R&D technology platform with independent intellectual property rights, while Huadong Medicine has deep expertise in innovative drug development, particularly rich experience in clinical and commercialization of cardiovascular drugs. In the future, we will work together with Synerk to accelerate the development of SNK-2726, aiming to benefit more patients with hypertension as soon as possible."
About SNK-2726
Synerk's proprietary siRNA drug SNK-2726 is a subcutaneously injectable RNAi therapeutic targeting angiotensinogen (AGT), currently in the preparation phase for IND submission for the treatment of hypertension. AGT is the most upstream precursor in the renin-angiotensin-aldosterone system (RAAS), and circulatory AGT primarily originates from the liver. Inhibiting AGT production can effectively block the RAAS pathway, regulating blood pressure. Preclinical study results show that SNK-2726 significantly suppresses AGT synthesis in the liver with long-lasting effects, leading to a sustained reduction in AGT protein levels, ultimately achieving a blood pressure-lowering effect.
About Synerk
Synerk is a biopharmaceutical company focused on developing RNA-targeted therapies, with branches in Boston, USA, and Suzhou and Beijing, China. The founders are industry experts with extensive experience in the discovery and development of RNA therapies. Synerk aims to become a world-class RNA-targeted therapy company by advancing products with the potential to be first-in-class or best-in-class, addressing diseases that are difficult to treat with current therapies.
For more information, please visit: www.synerk.cn
Statement
1. This news aims to share the company's frontier information, not for advertising purposes. The relevant information is not targeted at patients and is only for reference by healthcare professionals.
2. The content in this press release does not involve any recommendation for any drug and/or indication;
3. The information involved in this press release is for reference only and should not be considered as a substitute for professional medical guidance or as medical advice. If you wish to obtain specific disease diagnosis and treatment information, please follow the advice or guidance of doctors or other healthcare professionals.
4. As of the publication of this article, SNK-2726Not yet approved for marketing by the National Medical Products Administration;
5. This press release may contain certain forward-looking statements. These statements inherently involve significant risks and uncertainties. When using terms such as "expect," "believe," "forecast," "anticipate," "intend," and similar expressions related to our company, all are considered forward-looking statements. Our company has no obligation to continuously update these predictive statements.
These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts, and understandings of the management of our company regarding future events at the time of making the statements. These statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond the control of our company and are difficult to predict. Therefore, actual results may differ significantly from the information contained in these forward-looking statements due to changes and developments in our business, competitive environment, political, economic, legal, and social conditions.
Neither the Company, its directors nor its employees assume any obligation (a) to correct or update any forward-looking statements contained on this website; and (b) for any liability arising from or related to any forward-looking statement failing to materialize or becoming inaccurate.